Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK …
Management of chronic myeloid leukaemia (CML) has recently undergone dramatic
changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; …
changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; …
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory
S Saugues, C Lambert, E Daguenet, HJ Ansah… - Annals of …, 2022 - Springer
Guidelines for tyrosine kinase inhibitor (TKI)-treated chronic phase-chronic myeloid
leukemia (CML) management are essentially based on data from clinical research trials; …
leukemia (CML) management are essentially based on data from clinical research trials; …
Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question
K Sweet, J Pinilla-Ibarz - Critical Reviews in Oncology/Hematology, 2016 - Elsevier
Response to frontline BCR-ABL1-targeted tyrosine kinase inhibitor (TKI) therapy is
associated with an improved prognosis for patients with chronic myeloid leukemia (CML) …
associated with an improved prognosis for patients with chronic myeloid leukemia (CML) …
Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?
AE Eskazan, MC Ar, T Soysal - Expert Review of Hematology, 2016 - Taylor & Francis
Management of chronic myeloid leukemia (CML) has undergone a rapid evolution with the
invention of imatinib–the first tyrosine kinase inhibitor (TKI) approved for the treatment of …
invention of imatinib–the first tyrosine kinase inhibitor (TKI) approved for the treatment of …
Impact of ELN recommendations in the management of first‐line treated chronic myeloid leukaemia patients: a French cross‐sectional study
G Etienne, F Huguet, A Guerci‐Bresler… - British journal of …, 2016 - Wiley Online Library
The availability of tyrosine kinase inhibitors has extended therapeutic options for chronic
myeloid leukaemia (CML) patients. Monitoring recommendations and clinical response …
myeloid leukaemia (CML) patients. Monitoring recommendations and clinical response …
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: follow‐up of patients diagnosed 2002–2017 in a complete coverage …
Tyrosine kinase inhibitors (TKIs) have profoundly improved the clinical outcome for patients
with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the …
with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the …
[HTML][HTML] Treatment outcome in a population-based,'real-world'cohort of patients with chronic myeloid leukemia
IGP Geelen, N Thielen, JJWM Janssen… - …, 2017 - ncbi.nlm.nih.gov
Evaluations of the 'real-world'efficacy and safety of tyrosine kinase inhibitors in patients with
chronic myeloid leukemia are scarce. A nationwide, population-based, chronic myeloid …
chronic myeloid leukemia are scarce. A nationwide, population-based, chronic myeloid …
[HTML][HTML] Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors
P Chopade, LP Akard - Clinical Lymphoma Myeloma and Leukemia, 2018 - Elsevier
Most patients with chronic myeloid leukemia (CML) receiving treatment with BCR-ABL1
tyrosine kinase inhibitors (TKIs) will achieve favorable responses. Moreover, TKI therapy …
tyrosine kinase inhibitors (TKIs) will achieve favorable responses. Moreover, TKI therapy …
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
This study assessed the relevance of 2013 European LeukaemiaNet (ELN) response
categories on patients treated with common frontline tyrosine kinase inhibitors (TKI) in …
categories on patients treated with common frontline tyrosine kinase inhibitors (TKI) in …
A multicenter retrospective chart review study of treatment and disease patterns and clinical outcomes of patients with chronic-phase chronic myeloid leukemia in third …
FE Nicolini, F Huguet, L Huynh, C Xu, C Bouvier… - Cancers, 2023 - mdpi.com
Simple Summary Many patients with chronic-phase chronic myeloid leukemia (CP-CML)
treated with a tyrosine kinase inhibitor (TKI) experience disease progression and switch to …
treated with a tyrosine kinase inhibitor (TKI) experience disease progression and switch to …